Arca
Skip to content
Tools
Tools

S1PR1: Sphingosine 1-phosphate receptor 1

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

G protein-coupled receptor for the bioactive lysosphingolipid sphingosine 1-phosphate (S1P) that seems to be coupled to the G(i) subclass of heteromeric G proteins.

  • Drugs that act on it: 6
  • Approved: 4
  • In phases 1 to 3: 2
  • Sponsors: 6
  • Type: Protein

Who Is On It, and How Far Along

Every drug ChEMBL records acting on S1PR1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule

Approved4

  • Ozanimod
  • Etrasimod
  • Siponimod
  • Ponesimod

Phase 32

  • Cenerimod
  • Mocravimod

Phase 20

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      Modalities

      Drugs on this target by ChEMBL molecule type.

      • Small molecule6100%

      The Landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 4 of 6 act as: Sphingosine 1-phosphate receptor Edg-1 agonist; the rest name their own mechanism.
      OzanimodApprovedBristol-Myers SquibbSmall moleculeModulatorSphingosine 1-phosphate receptor Edg-1 modulator17—
      EtrasimodApprovedPfizerSmall moleculeAgonist—12—
      SiponimodApprovedNovartis PharmaceuticalsSmall moleculeAgonist—6—
      PonesimodApprovedVanda PharmaceuticalsSmall moleculeAgonist—4—
      CenerimodPhase 3ViatrisSmall moleculeModulatorSphingosine 1-phosphate receptor Edg-1 modulator5—
      MocravimodPhase 3Priothera SASSmall moleculeAgonist—1—

      Open Trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 30 in all, from ClinicalTrials.gov.
      Comaprison of Efficacy and Safety Between Etrasimod vs Mesalazine in Chinese Adults With Active UCEtrasimodPhase 4Not yet recruitingSir Run Run Shaw Hospital2026-08-24
      A Study to Evaluate the Safety, Tolerability, PK and Preliminary Efficacy of HX15001 Combined With Etrasimod in Moderate-severe Ulcerative ColitisEtrasimodPhase 1Not yet recruitingHelixon Biotechnology (Suzhou) Co., Ltd2026-08-17
      Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to ZeposiaOzanimod—RecruitingBristol-Myers Squibb2026-07-29
      A National Multicenter Study of Etrasimod for the Treatment of Patients With Active UCEtrasimod—Not yet recruitingTang-Du Hospital2026-07-15
      Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative ColitisPonesimodPhase 3RecruitingVanda Pharmaceuticals2026-07-07
      Etrasimod as Prevention of PouchitisEtrasimodPhase 2RecruitingMaia Kayal2026-03-23
      A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative ColitisEtrasimodPhase 2RecruitingPfizer2026-03-13
      An Observational Study to Learn About Velsipity After Long Term Use in Patients With Ulcerative ColitisEtrasimod—Active, not recruitingPfizer2026-03-10
      Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque PsoriasisPonesimodPhase 3RecruitingVanda Pharmaceuticals2026-01-23
      Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative ColitisOzanimod—RecruitingBristol-Myers Squibb2025-12-08
      A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE)CenerimodPhase 2Active, not recruitingViatris Pharmaceuticals Co., Ltd.2025-12-05
      Efficacy and Safety of Etrasimod in Elderly Patients With Ulcerative ColitisEtrasimodNot applicableRecruitingShowa Inan General Hospital2025-11-24
      A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular TreatmentCenerimodPhase 3RecruitingViatris Innovation GmbH2025-10-01
      Ozanimod in Patients With Alzheimer's DiseaseOzanimodPhase 2RecruitingChenXiaoChun2025-03-07
      Repurposing Siponimod for Alzheimer's DiseaseSiponimodPhase 2RecruitingSt. Joseph's Hospital and Medical Center, Phoenix2024-10-15
      Prospective Evaluation of Sequencing From antiCD-20 Therapies to OzanimodOzanimodPhase 4RecruitingUniversity of Colorado, Denver2024-07-31
      Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus ErythematosusCenerimodPhase 3Enrolling by invitationViatris Innovation GmbH2024-06-26
      Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple SclerosisOzanimodPhase 3RecruitingBristol-Myers Squibb2024-05-10
      An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative ColitisEtrasimod—Active, not recruitingPfizer2024-05-03
      A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple SclerosisOzanimodPhase 4Active, not recruitingBristol-Myers Squibb2024-05-02
      A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their InfantsOzanimod—Active, not recruitingBristol-Myers Squibb2023-11-15
      A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their InfantsOzanimod—Active, not recruitingBristol-Myers Squibb2023-11-13
      A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their BabiesPonesimod, Siponimod—Active, not recruitingBiogen2023-01-18
      A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus ErythematosusCenerimodPhase 3Active, not recruitingViatris Innovation GmbH2023-01-05
      A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus ErythematosusCenerimodPhase 3Active, not recruitingViatris Innovation GmbH2022-12-13
      Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCTMocravimodPhase 3RecruitingPriothera SAS2022-06-23
      Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With MayzentSiponimod—RecruitingNovartis Pharmaceuticals2021-06-21
      Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple SclerosisSiponimodPhase 3Active, not recruitingNovartis Pharmaceuticals2021-06-15
      Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMSPonesimod, SiponimodPhase 4Active, not recruitingThe Cleveland Clinic2018-05-24
      Determinants of Warfarin MetabolismSiponimodNot applicableRecruitingHadassah Medical Organization2005-09-13

      Diseases Most Associated With It

      Open Targets association score, 0 to 1; all associations
      Crohn disease
      0.39
      Kidney transplant
      0.34
      Breast benign neoplasm
      0.30
      Non-small cell lung carcinoma
      0.29
      Preeclampsia
      0.29
      Response to stimulus
      0.25

      Genes and Related Targets

      Complexes and families that share a gene with this target
      Genes
      S1PR1

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4333, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P21453, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.